Middle East & Africa Breast Cancer Therapeutics Market

The Middle East & Africa breast cancer therapeutics market was valued at US$ 762.61 million in 2022 and is expected to reach US$ 1,342.86 million by 2030; it is estimated to grow at a CAGR of 7.3% from 2022 to 2030.

Growing Burden of Breast Cancer Fuels the Middle East & Africa Breast Cancer Therapeutics Market

Breast cancer is considered the most common cancer among women worldwide, and its incidence is increasing globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and environmental factors contribute to the rising prevalence of breast cancer. According to WHO, in 2020, 685,000 people died worldwide from breast cancer, accounting for 2.3 million new diagnoses. Breast cancer is one of the most common cancers globally, with 7.8 million women alive as of the end of 2020 who had received a diagnosis within the previous five years. All across the world, breast cancer affects women at any age after adolescence. However, its prevalence rises with age. With the rise in breast cancer cases, there is an increasing need for effective and targeted therapies to improve patient outcomes. This has led to a surge in research and development activities in breast cancer therapeutics. Therefore, the growing burden of breast cancer drives the Middle East & Africa breast cancer therapeutics market.

Middle East & Africa Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in the Middle East & Africa is segmented into UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Changing healthcare infrastructure and public-private partnerships between government and international players are strengthening the healthcare sector in the country. These partnerships and privatization efforts align with the policies included in the "Vision 2030" strategy by the Saudi government to transform the national economy. As per the International Trade Administration, the Saudi Arabian government invested about US$ 65 billion to build the country's healthcare infrastructure as part of Vision 2030. In addition, it intends to increase private sector contribution from 40% to 65% by 2030, with a focus on the privatization of 290 hospitals and 2,300 primary health centers. Increased investment in infrastructure and innovation is anticipated to encourage growth in the market.

In June 2023, MSD GCC expanded its oncology research partnership with The Department of Health Abu Dhabi (DoH). The deal, signed at the BIO International Convention 2023, signified the continuation of a long-term collaboration between the two entities. Within the framework of their renewed partnership, the two parties will collaborate to initiate two observational research studies in the field of oncology, focusing on non-small cell lung cancer and triple-negative breast cancer. The studies aim to advance the ability to address the healthcare challenges associated with these diseases and improve patient outcomes. Therefore, the growing efforts of the companies to spread awareness and development of new and innovative products in the country significantly contribute to the growth of the breast cancer therapeutics market in the UAE.

In October 2021, the National Bank of Kuwait (NBK) launched an annual campaign to promote women's health during breast cancer awareness month. The campaign is part of the Banks ongoing campaign to raise social awareness regarding breast cancer and promote its ways of prevention. Therefore, the above-mentioned factors significantly fuel the breast cancer therapeutics market growth.

Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Breast Cancer Therapeutics Strategic Insights

Strategic insights for the Middle East & Africa Breast Cancer Therapeutics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Breast Cancer Therapeutics Report Scope

Middle East & Africa Breast Cancer Therapeutics Regional Insights

The geographic scope of the Middle East & Africa Breast Cancer Therapeutics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Breast Cancer Therapeutics Market Segmentation

The Middle East & Africa breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the Middle East & Africa breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Middle East & Africa breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the Middle East & Africa breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the Middle East & Africa breast cancer therapeutics market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Middle East & Africa breast cancer therapeutics market.